Business, Health Care

Catalent, Inc. reports first quarter fiscal 2021 results

 Q1’21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1’20. On an organic basis, constant currency net revenue in Q1’21 grew 20% compared to Q1’20.  Q1’21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or

News Now!, Politics

Has the Court learned nothing from Bush v. Gore?

Doesn’t seem like it has. You remember the legal horror show called Bush v. Gore? The Supreme Court couldn’t possibly replicate that. But don’t underestimate the justices’ capacity for self-inflicted wounds. The sequel’s being scripted and it may be worse. Twenty years ago,

Business, Health Care

DESTINY-Breast05 head-to-head phase 3 trial of ENHERTU® versus T-DM1 initiated in patients with HER2 positive early breast cancer at high risk after neo-adjuvant therapy

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of DESTINY-Breast05, a global phase 3, head-to-head trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki) versus ado-trastuzumab emtansine (T-DM1) as adjuvant therapy in patients with